Bio-Techne Corporation
NASDAQ:TECHBiotechnology
-$1.03 today
- Market cap
- $11.43B
- Beta
- 1.36
- P/E (TTM)
- 78.3
- EPS (TTM)
- $0.70
- Dividend yield
- 0.58%
Volume 2.63M
Average 2.66M
TECH Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Bio-Techne CorporationNASDAQ: TECH
Gross Profit · Q1 FY2027 · quarter ended Sep 2026
Gross profit growth accelerates
Q1 FY2027 gross profit of $196.62M rose 4.5% year over year, ahead of the +1.5% change in trailing-twelve-month gross profit. Sequentially, it fell 7.0% from the prior quarter. Over 3 fiscal years it compounded at +1.3% a year.
Context
- Gross profit amounted to 65.8% of revenue in FY2026, up 1.0 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.5% holds above the trailing-twelve-month pace of +1.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2026
- 799.07M USD
- Year-over-year change
- +1.1%
- 4-year CAGR
- +1.4%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 799.07M | +1.1% |
| FY2025 | 2025-06-30 | 790.27M | +2.7% |
| FY2024 | 2024-06-30 | 769.73M | -0.0% |
| FY2023 | 2023-06-30 | 769.82M | +1.8% |
| FY2022 | 2022-06-30 | 756.5M | — |
Gross Profit vs competitors
How TECH compares with its peers on the latest reported figures
- TECH's LTM Sep 2026 gross profit of $807.58M is the 8th highest of the 11 companies compared; the peer median is $1.43B.
- Its year-over-year change of +1.5% is the 4th highest of 10, against a peer median of +0.8%.
- Gross profit amounts to 65.8% of revenue for TECH, versus a peer median of 52.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $19.62B | +10.8% | -1.4% | 41.4% | |
| LTM Sep 2026 | $15.01B | +0.8% | -2.6% | 58.6% | |
| LTM Jul 2026 | $3.96B | +10.2% | -0.7% | 53.7% | |
| LTM Jun 2026 | $1.63B | -1.6% | +6.5% | 46.7% | |
| LTM Jul 2026 | $1.52B | +0.3% | -4.9% | 52.1% | |
| LTM Jun 2026 | $1.34B | -0.4% | -5.0% | 51.9% | |
| LTM Jun 2026 | $1.3B | +1.1% | -2.3% | 61.8% | |
| LTM Sep 2026 | $807.58M | +1.5% | +1.3% | 65.8% | |
| LTM Sep 2026 | $444.65M | +0.6% | +3.9% | 71.9% | |
ALMRAlamar Biosciences, Inc. | FY2025 | $41.71M | — | — | 56.2% |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
| Peer median (excluding TECH) | $1.43B | +0.8% | -1.4% | 52.9% | |
Competitors are the stored peer set for TECH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B |
| Cost of Revenue | 349.1M | 366.89M | 389.34M | 429.36M | 415.97M |
| Gross Profit | 756.5M | 769.82M | 769.73M | 790.27M | 799.07M |
| Gross Margin | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Research & Development | 87.14M | 92.49M | 96.66M | 99.5M | 94.77M |
| Selling, General & Admin | 339M | 352.44M | 393.32M | 415.1M | 452.42M |
| Operating Expenses | 459.91M | 470.87M | 563.04M | 688.02M | 547.18M |
| Depreciation & Amortization | 101.07M | 107.24M | 111.71M | 109.9M | 97.36M |
| EBITDA | 413.76M | 457.11M | 313.14M | 216.88M | 343.44M |
| EBITDA Margin | 37.4% | 40.2% | 27.0% | 17.8% | 28.3% |
| Operating Income | 296.59M | 298.94M | 206.69M | 102.26M | 251.89M |
| Operating Margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Interest Income | 794K | 3.41M | 3.32M | 3.89M | 0 |
| Interest Expense | 11.31M | 11.22M | 15.74M | 8.51M | 5.41M |
| Other Income / Expenses | 4.8M | 39.72M | (21M) | (3.79M) | (11.21M) |
| Income Before Tax | 301.39M | 338.66M | 185.69M | 98.46M | 240.68M |
| Pre-Tax Margin | 27.3% | 29.8% | 16.0% | 8.1% | 19.8% |
| Income Tax Expense | 38.29M | 53.22M | 17.58M | 25.06M | 58.82M |
| Net Income | 272.05M | 285.26M | 168.11M | 73.4M | 181.86M |
| Net Margin | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (Basic) | 1.73 | 1.81 | 1.07 | 0.47 | 1.17 |
| EPS (Diluted) | 1.66 | 1.76 | 1.05 | 0.46 | 1.16 |
| Weighted Avg Shares | 156.88M | 157.18M | 157.71M | 157.52M | 155.96M |
| Weighted Avg Shares (Diluted) | 164.12M | 161.86M | 160.77M | 159.72M | 157.01M |
Bio-Techne Corporation
NASDAQ:TECH
Intrinsic Alpha fair value
Locked
Current Price
$72.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.